Transcatheter valve-in-valve implantation for failed mitral prosthesis: the first experience in Japan.

Cardiovasc Interv Ther

Department of Cardiovascular Surgery, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba, Sendai, Miyagi, 980-0873, Japan.

Published: January 2017

An 82-year-old woman had a history of mitral valve replacement with a 25-mm MOSAIC (Medtronic, USA) for severe mitral regurgitation (MR) 8 years previously. Recently, she developed heart failure due to MR secondary to prosthetic valve failure. She underwent transcatheter valve-in-valve implantation with a 23-mm SAPIEN XT (Edwards Lifesciences, USA) to the prosthetic mitral valve by transapical approach. To our knowledge, this is the first reported case of transcatheter valve implantation for failed mitral prosthetic valve using valve-in-valve technique in Japan.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12928-015-0374-9DOI Listing

Publication Analysis

Top Keywords

transcatheter valve-in-valve
8
valve-in-valve implantation
8
implantation failed
8
failed mitral
8
mitral valve
8
prosthetic valve
8
mitral
5
valve
5
mitral prosthesis
4
prosthesis experience
4

Similar Publications

Background: Balloon-assisted bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BA-BASILICA) enables valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) in patients at risk of coronary artery obstruction. However, its efficacy in patients with severely calcified leaflets remains unclear.

Case Summary: We report a 78-year-old woman with a deteriorated 21 mm Carpentier-Edwards PERIMOUNT Magna valve.

View Article and Find Full Text PDF

In recent years, the use of transcatheter valve-in-valve implantation in the mitral position (TMVI) for the treatment of mitral valve pathology following ring or bioprosthetic implantation has emerged as a less invasive option in comparison to repeated mitral valve surgery (RMVS). We aimed to compare the early and mid-term results of these two strategies. We retrospectively analyzed all patients who underwent a mitral intervention in our institution between 2005 and 2022.

View Article and Find Full Text PDF

Introduction: Transcatheter mitral valve-in-valve replacement (TMVR ViV) is becoming a favorable, less invasive procedure among high-risk patients to manage mitral valve dysfunction. We aimed to investigate the trends of the predictors and outcomes of the procedure.

Methods: The national inpatient sample databases of 2016-2020 were analyzed using STATA 17 software and ICD-10 codes for TMVR ViV, with stratification for mitral stenosis (MS) or Mitral regurgitation (MR) as etiology for prosthetic valve dysfunction.

View Article and Find Full Text PDF

Same-Day Discharge After Uncomplicated Transcatheter Tricuspid Valve-In-Valve Implantation.

Catheter Cardiovasc Interv

December 2024

Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, USA.

Background: Tricuspid valve-in-valve (TVIV) implantation has traditionally included post-procedure overnight in-hospital observation with next-day discharge. Recently, our practice has shifted toward same-day discharge for most patients after vascular access site hemostasis and adequate recovery from anesthesia. However, data on the safety of this approach remains scarce.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!